HP HEALTH SOLUTIONS GERMANY GMBH

Their core work

HP Health Solutions develops ultra-fast molecular diagnostics devices — portable, battery-powered PCR platforms designed for point-of-care testing outside traditional laboratories. Their core technology is laser-based PCR that delivers rapid pathogen detection, initially targeting Ebola-family viruses (Filoviruses) and then tuberculosis, including multi-drug resistant strains. More recently they contributed miniaturized disposable molecular testing hardware aimed at coronavirus detection for first responders and home use.

What they specialise in

How they've shifted over time

HP Health Solutions started in 2015 with ultra-fast molecular diagnostics for high-consequence pathogens (Ebola/filoviruses) under the FILODIAG project — a high-stakes niche requiring speed and biosafety. By 2017-2020, they pivoted toward tuberculosis point-of-care testing (PITBUL), adding cloud connectivity and targeting multi-drug resistant strains — a far larger global health market. Their most recent involvement (DECISION, 2020-2024) shows a shift toward miniaturized, disposable platforms for pandemic response, suggesting they are moving from specialized lab-adjacent devices toward mass-deployable home and first-responder testing.

They are moving from specialized high-biosafety pathogen detection toward mass-market disposable molecular diagnostics for pandemic preparedness and decentralized healthcare.

How they like to work

HP Health Solutions primarily leads projects — they coordinated 2 of their 3 H2020 projects, indicating they drive the research agenda rather than just contributing components. With 11 unique partners across 8 countries from only 3 projects, they build moderately sized international consortia and do not appear to repeat partners frequently, suggesting they assemble mission-specific teams. Their coordinator role and SME status make them an unusually entrepreneurial lead for health diagnostics projects.

They have collaborated with 11 distinct partners across 8 countries, showing a broad European reach despite being a small company. Their network spans the health diagnostics and medical device ecosystem rather than being concentrated in one geographic cluster.

What sets them apart

HP Health Solutions occupies a rare niche: a German SME that owns proprietary ultra-fast laser PCR technology and has demonstrated it across multiple pathogen targets (Ebola, TB, coronavirus). Unlike academic groups that publish on diagnostics or large device manufacturers that integrate off-the-shelf components, they develop the core rapid-heating PCR engine and build complete portable platforms around it. For consortium builders, they bring both the IP and the product development capability to take molecular diagnostics from bench to field deployment.

Highlights from their portfolio

• FILODIAG
  Their first coordinated project tackling ultra-fast Ebola diagnostics under IMI2 funding — established their laser PCR technology platform with EUR 1.46M EC contribution.
• PITBUL
  Largest single grant (EUR 1.64M), coordinated by them, extending their platform to tuberculosis with cloud connectivity — demonstrates commercial scaling ambition.
• DECISION
  Pandemic-response pivot to miniaturized disposable coronavirus diagnostics — shows ability to rapidly adapt core technology to emerging health crises.